Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | CH5N3.ClH |
| Molecular Weight | 95.531 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC(N)=N
InChI
InChIKey=PJJJBBJSCAKJQF-UHFFFAOYSA-N
InChI=1S/CH5N3.ClH/c2-1(3)4;/h(H5,2,3,4);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | CH5N3 |
| Molecular Weight | 59.0705 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.
Originator
Sources: https://d-nb.info/1059797615/34
Curator's Comment: Original article: A. Strecker, Liebigs Ann. Chem. 1861, 118, 151-177.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2362996 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | GUANIDINE HYDROCHLORIDE Approved UseGuanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis. Launch Date1939 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Presynaptic imidazoline receptors. New developments in characterization and classification. | 1999 Jun 21 |
|
| [The study of the Ca2+ role in cytotoxic response of human cells in culture to the action of xenobiotics]. | 2000 |
|
| The picornavirus replication inhibitors HBB and guanidine in the echovirus-9 system: the significance of viral protein 2C. | 2000 Apr |
|
| Dihydrofolate reductase from Thermotoga maritima. | 2001 |
|
| Expression and refolding of full-length human TIMP-1. | 2001 |
|
| Evolution and physiological roles of phosphagen systems. | 2001 |
|
| Demineralized bone matrix as a biological scaffold for bone repair. | 2001 Apr |
|
| Kinetics of unfolding and folding from amide hydrogen exchange in native ubiquitin. | 2001 Apr |
|
| Strain-specified relative conformational stability of the scrapie prion protein. | 2001 Apr |
|
| The structure of human mitochondrial branched-chain aminotransferase. | 2001 Apr |
|
| High-sensitivity fluorescence anisotropy detection of protein-folding events: application to alpha-lactalbumin. | 2001 Apr |
|
| Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent. | 2001 Apr 12 |
|
| Second-site revertants of a low-sodium-affinity mutant of the Na+/H+ exchanger reveal the participation of TM4 into a highly constrained sodium-binding site. | 2001 Apr 24 |
|
| Equilibrium unfolding of dimeric desulfoferrodoxin involves a monomeric intermediate: iron cofactors dissociate after polypeptide unfolding. | 2001 Apr 24 |
|
| Intensely positively charged perineuronal nets in the adult rat brain as detected by staining with anionic iron colloid. | 2001 Feb |
|
| Human recombinant interferon-inducible protein-10: intact disulfide bridges are not required for inhibition of hematopoietic progenitors and chemotaxis of T lymphocytes and monocytes. | 2001 Feb |
|
| Stabilization of hen egg white lysozyme by a cavity-filling mutation. | 2001 Feb |
|
| Metric engineering of soft molecular host frameworks. | 2001 Feb |
|
| [Discovery of cis-preference of aromatic N-methylamides and its application to molecular constructions]. | 2001 Feb |
|
| Erythrocyte transketolase activity and guanidino compounds in hemodialysis patients. | 2001 Feb |
|
| Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor. | 2001 Feb |
|
| Uremic concentrations of guanidino compounds inhibit neutrophil superoxide production. | 2001 Feb |
|
| Endogenous guanidino compounds as uremic neurotoxins. | 2001 Feb |
|
| Human abdominal aortic aneurysm is characterized by decreased versican concentration and specific downregulation of versican isoform V(0). | 2001 Feb 1 |
|
| Spontaneous and flow-induced Ca2+ transients in retracted regions in endothelial cells. | 2001 Feb 16 |
|
| Molecular specificities of antibodies against ovine and murine recombinant prion proteins. | 2001 Feb 16 |
|
| Solid-phase guanidinylation as a diversification strategy of poly-L-proline type II peptide mimic scaffolds. | 2001 Feb 22 |
|
| Equilibrium unfolding of Bombyx mori glycyl-tRNA synthetase. | 2001 Feb 9 |
|
| Collision-induced dissociation of ring-opened cyclic depsipeptides with a guanidino group by electrospray ionization/ion trap mass spectrometry. | 2001 Jan |
|
| Phaeochromocytoma: an unusual cause of hypertension in pregnancy. | 2001 Jan |
|
| Cellular responses of NG108-15 and SK-N-MC lines to sweet and bitter tastants as measured by extracellular acidification rates. | 2001 Jan 1 |
|
| Folding-unfolding of goat alpha-lactalbumin studied by stopped-flow circular dichroism and molecular dynamics simulations. | 2001 Jan 1 |
|
| Limited tryptic hydrolysis of pea legumin: molecular mass and conformational stability of legumin-T. | 2001 Jan 10 |
|
| Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains. | 2001 Jan 12 |
|
| Surprisingly high stability of barley lipid transfer protein, LTP1, towards denaturant, heat and proteases. | 2001 Jan 19 |
|
| A kinetic folding intermediate probed by native state hydrogen exchange. | 2001 Jan 19 |
|
| [Antibody avidity: use for the diagnosis of HIV early infection]. | 2001 Jan-Feb |
|
| Structural basis of the Na+/H+ exchanger regulatory factor PDZ1 interaction with the carboxyl-terminal region of the cystic fibrosis transmembrane conductance regulator. | 2001 Jun 8 |
|
| Proteoglycans and hyaluronan in human fetal membranes. | 2001 Mar |
|
| Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release. | 2001 Mar |
|
| Major differences in stability and dimerization properties of two chimeric mutants of human stefins. | 2001 Mar 1 |
|
| The synthesis of beta-peptides containing guanidino groups. | 2001 Mar 12 |
|
| Matrix proteins from insect pliable cuticles: are they flexible and easily deformed? | 2001 Mar 15 |
|
| Structural alterations and inhibition of unisite and multisite ATP hydrolysis in soluble mitochondrial F1 by guanidinium chloride. | 2001 Mar 20 |
|
| Probing local conformational changes during equilibrium unfolding of firefly luciferase: fluorescence and circular dichroism studies of single tryptophan mutants. | 2001 Mar 23 |
|
| The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. | 2001 Mar 30 |
|
| The structure of denatured alpha-lactalbumin elucidated by the technique of disulfide scrambling: fractionation of conformational isomers of alpha-lactalbumin. | 2001 Mar 30 |
|
| The dimerization of folded monomers of ribulose 1,5-bisphosphate carboxylase/oxygenase. | 2001 Mar 9 |
|
| Proton and metal ion-dependent assembly of a model diiron protein. | 2001 May |
|
| Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. | 2001 May 15 |
Sample Use Guides
Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.
Route of Administration:
Oral
Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:49:51 GMT 2025
by
admin
on
Mon Mar 31 17:49:51 GMT 2025
|
| Record UNII |
3YQC9ZY4YB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C45678
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
CONCEPT | Industrial Aid | ||
|
C47551
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
755884
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
50676
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | RxNorm | ||
|
50-01-1
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
5742
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
SUB14035MIG
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
1302134
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
DBSALT000737
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
DTXSID7058757
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
CHEMBL821
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
m5867
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | Merck Index | ||
|
Guanidinium chloride
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
3YQC9ZY4YB
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
32735
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
100000077897
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY | |||
|
200-002-3
Created by
admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|